JP2015110588A5 - - Google Patents

Download PDF

Info

Publication number
JP2015110588A5
JP2015110588A5 JP2014263345A JP2014263345A JP2015110588A5 JP 2015110588 A5 JP2015110588 A5 JP 2015110588A5 JP 2014263345 A JP2014263345 A JP 2014263345A JP 2014263345 A JP2014263345 A JP 2014263345A JP 2015110588 A5 JP2015110588 A5 JP 2015110588A5
Authority
JP
Japan
Prior art keywords
peptide
use according
klh
formulated
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014263345A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015110588A (ja
JP5989074B2 (ja
Filing date
Publication date
Priority claimed from AT0095208A external-priority patent/AT506820B1/de
Application filed filed Critical
Publication of JP2015110588A publication Critical patent/JP2015110588A/ja
Publication of JP2015110588A5 publication Critical patent/JP2015110588A5/ja
Application granted granted Critical
Publication of JP5989074B2 publication Critical patent/JP5989074B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2014263345A 2008-06-12 2014-12-25 アミロイドーシス治療のための化合物 Expired - Fee Related JP5989074B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA952/2008 2008-06-12
AT0095208A AT506820B1 (de) 2008-06-12 2008-06-12 Vakzine gegen alzheimer-krankheit

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011512780A Division JP2011522840A (ja) 2008-06-12 2009-06-12 アミロイドーシス治療のための化合物

Publications (3)

Publication Number Publication Date
JP2015110588A JP2015110588A (ja) 2015-06-18
JP2015110588A5 true JP2015110588A5 (enExample) 2015-11-05
JP5989074B2 JP5989074B2 (ja) 2016-09-07

Family

ID=41401983

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011512780A Pending JP2011522840A (ja) 2008-06-12 2009-06-12 アミロイドーシス治療のための化合物
JP2014073229A Expired - Fee Related JP5984867B2 (ja) 2008-06-12 2014-03-31 アミロイドーシス治療のための化合物
JP2014263345A Expired - Fee Related JP5989074B2 (ja) 2008-06-12 2014-12-25 アミロイドーシス治療のための化合物

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2011512780A Pending JP2011522840A (ja) 2008-06-12 2009-06-12 アミロイドーシス治療のための化合物
JP2014073229A Expired - Fee Related JP5984867B2 (ja) 2008-06-12 2014-03-31 アミロイドーシス治療のための化合物

Country Status (14)

Country Link
US (1) US8409581B2 (enExample)
EP (1) EP2310033B1 (enExample)
JP (3) JP2011522840A (enExample)
KR (1) KR20110036039A (enExample)
CN (1) CN102123728B (enExample)
AT (2) AT506820B1 (enExample)
AU (1) AU2009257168B2 (enExample)
BR (1) BRPI0915136A2 (enExample)
CA (1) CA2723967A1 (enExample)
ES (1) ES2392789T3 (enExample)
IL (1) IL209894A (enExample)
MX (1) MX2010013657A (enExample)
RU (1) RU2491953C2 (enExample)
WO (1) WO2009149485A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
CN103459421B (zh) 2011-03-16 2017-07-14 前体生物药物股份公司 诊断性抗体测定
GB201113570D0 (en) 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
RS53496B1 (sr) 2011-10-04 2015-02-27 Affiris Ag POSTUPAK ZA DETEKCIJU Aβ-SPECIFIČNIH ANTITELA U BIOLOŠKOM UZORKU
EP2659908A1 (en) 2012-05-01 2013-11-06 Affiris AG Compositions
US9102752B2 (en) * 2013-03-15 2015-08-11 United Biomedical, Inc. Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer's type
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
JP2017514831A (ja) * 2014-04-29 2017-06-08 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ アルツハイマー病（ａｄ）の処置および予防
DK3137094T3 (da) 2014-04-29 2023-02-27 Advantage Therapeutics Inc Behandling og forebyggelse af alzheimers sygdom (ad)
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
US10774120B2 (en) 2015-11-09 2020-09-15 The University Of British Columbia Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
KR102964291B1 (ko) 2015-11-09 2026-05-13 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 에피토프 및 이에 대한 항체
CA3004482A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
KR102550991B1 (ko) 2016-07-18 2023-07-04 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에 대한 항체
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
ES2984844T3 (es) 2017-07-18 2024-10-31 Univ British Columbia Anticuerpos contra beta amiloide
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
RU2679080C1 (ru) * 2018-04-17 2019-02-05 Александр Олегович Морозов Пептид и способ лечения болезни альцгеймера
MX2021008035A (es) 2018-12-31 2021-12-10 United Neuroscience Ltd Inmunógenos peptídicos dirigidos al péptido relacionado con el gen de la calcitonina (cgrp) y sus formulaciones para la prevención y el tratamiento de la migraña.
CN115925987B (zh) * 2022-02-28 2026-05-05 安域生物科技(杭州)有限公司 基于β-淀粉样蛋白修饰的抗原多肽及其应用
CN119136838A (zh) 2022-02-28 2024-12-13 特瑞德姆生物科技有限责任两合公司 由至少一种β-葡聚糖或甘露聚糖组成或包含至少一种β-葡聚糖或甘露聚糖的偶联物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5780587A (en) * 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
JP2002510641A (ja) * 1998-04-06 2002-04-09 アドヴァンスト・イミューニット・インク 神経退化疾患治療用短ペプチド
NO314086B1 (no) * 1998-05-08 2003-01-27 Gemvax As Peptider og farmasöytiske sammensetninger inneholdende disse, nukleinsyresekvenser som koder for slike peptider, plasmider og virusvektoreromfattende slike DNA-sekvenser samt anvendelse av disse for fremstilling avfarmasöytiske preparater til
ES2345746T3 (es) * 1998-05-21 2010-09-30 University Of Tennessee Research Foundation Metodos para la eliminacion de amiloide usando anticuerpos antiamiloide.
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US20040067535A1 (en) * 2002-10-03 2004-04-08 Life Sciences Development Corp. Alzheimer's disease linked genes
CN1753662A (zh) * 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
EP1440981A3 (en) * 2003-01-21 2005-11-23 Research Association for Biotechnology Full-length human cdna
US7358331B2 (en) * 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
AT500483B1 (de) * 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
CA2790433A1 (en) * 2004-10-25 2006-05-26 Northwestern University Anti-addl antibodies and uses thereof
WO2006136906A2 (en) * 2005-06-17 2006-12-28 Epfl Ecole Polytechnique Fédérale De Lausanne Switch-peptides as tool for the study of fibrillogenesis
NZ568012A (en) * 2005-12-12 2012-07-27 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
CN101421299A (zh) * 2006-02-22 2009-04-29 株式会社林原生物化学研究所 用于诱导产生抗淀粉样β肽抗体的肽疫苗

Similar Documents

Publication Publication Date Title
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
UA124347C2 (uk) Циклічна динуклеотидна сполука
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
JOP20180009A1 (ar) مركبات مثبط فيروس hiv
JP2013519675A5 (enExample)
JP2015517488A5 (enExample)
CO2018004776A2 (es) Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana
RU2017114352A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
JP2016518337A5 (enExample)
JP2019516735A5 (enExample)
EP3932907A3 (en) Dextromethorphan analogs and combinations of deuterated dextromethorphan and nortriptyline for use in treating agitation and/or aggression
EA201691789A1 (ru) Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
JP2016510326A5 (enExample)
CO2016003340A2 (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
PH12015502406A1 (en) Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof
AR094707A1 (es) Compuesto de quinazolin-4-amina, composición farmacéutica que lo comprende y su uso para el tratamiento de una enfermedad mediada por la quinasa rip2
MX2019002369A (es) Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial.
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
WO2015125152A3 (en) Pharmaceutical compositions of asenapine
JP2014148552A5 (enExample)
WO2016015798A9 (en) Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
EP4282485A3 (en) Dosage regimen for pegylated interferon
MX2023008839A (es) Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales.